查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1736412

全球纤维肌痛治疗市场规模（按药物类别、疗法、最终用户、区域范围和预测）

Global Fibromyalgia Treatment Market Size By Drug Class, By Treatment, By End-Users, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

纤维肌痛治疗的市场规模与预测

2024 年纤维肌痛治疗市场规模价值为 18.1176 亿美元，预计到 2032 年将达到 25.0828 亿美元，2026 年至 2032 年的复合年增长率为 4.15%。

  • 纤维肌痛治疗是指一系列医疗疗法、药物和其他解决方案，旨在控制纤维肌痛的症状，纤维肌痛是一种以广泛的肌肉骨骼疼痛、疲劳和认知障碍为特征的慢性疾病。
  • 它主要由医院、诊所和药房等医疗保健提供者用于治疗患有纤维肌痛的患者。
  • 纤维肌痛的常见治疗包括疼痛管理，如止痛药、抗忧郁症和抗惊厥药、物理治疗和咨询。
  • 它用于缓解症状、减轻疼痛以及控制睡眠障碍和忧郁症等相关疾病，从而改善纤维肌痛患者的生活品质。
  • 随着我们对纤维肌痛的认识不断加深，市场正在不断扩大，提供新的治疗选择，以满足越来越多寻求缓解这种慢性且常常使人衰弱的疾病的患者的需求。
  • 纤维肌痛症是一种长期疾病，会导致全身疼痛、疲劳以及睡眠、记忆和情绪问题。
  • 由于纤维肌痛症是一种具有多种症状的慢性疾病，因此治疗的重点是控制症状而不是治癒疾病。

纤维肌痛治疗的全球市场动态

影响全球纤维肌痛治疗市场的关键市场动态是：

关键市场驱动因素

  • 纤维肌痛盛行率不断上升：全球确诊患有纤维肌痛的患者数量正在增加，对有效治疗方案的需求也日益增长
  • 提高对疾病的认识：认识的提高和诊断方法的改进导致寻求治疗的患者增加。
  • 药物研发进展：美国国立卫生研究院 (NIH) 报告称，用于纤维肌痛研究的资金已从 2019 年的 1,300 万美元增加 38%，至 2023 年的 1,800 万美元。据美国食品药物管理局 (FDA) 称，目前有超过 25 项针对纤维肌痛治疗的临床试验处于不同审批阶段。製药公司正致力于开发新型、更有效的纤维肌痛药物，推动市场成长。
  • 改善医疗保健基础设施：医疗保健设施的发展，特别是在发展中地区，增加了获得纤维肌痛治疗的机会。
  • 非药物疗法的需求不断增长：对认知行为疗法 (CBT) 和物理復健等替代疗法的日益偏好正在推动市场成长。

主要市场挑战

  • 难以诊断：纤维肌痛很难诊断，因为症状与其他疾病重迭，妨碍及时治疗。
  • 开发中地区的认知度低：某些地区缺乏认知度和诊断工具限制了市场潜力。
  • 现有药物的副作用：许多纤维肌痛治疗都有显着的副作用，影响患者的依从性和市场成长。
  • 治疗费用高昂：药物和治疗费用可能会限制人们获得治疗的机会，尤其是对于低收入群体而言。
  • 缺乏治疗方法：由于没有永久治疗方法，市场仅限于症状治疗，长期疗效有限。

主要市场趋势

  • 个人化医疗的发展：对个人化治疗的日益关注正在推动纤维肌痛市场的发展。
  • 远端医疗整合：远端医疗平台变得越来越普遍，使患者更容易接受咨询和后续护理。
  • 非药物治疗的成长：越来越多的患者选择正念、针灸和运动计画等替代疗法。
  • 联合治疗：将药物治疗和非药物治疗结合起来以实现更全面的治疗的趋势日益增长。
  • 生技药品研究：目前正在对纤维肌痛症状根本原因的生技药品和新疗法进行新的研究，希望在未来找到更有效的解决方案。

目录

第一章 引言

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第二章调查方法

  • 资料探勘
  • 二次研究
  • 初步研究
  • 专家建议
  • 品质检查
  • 最终审核
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 资料来源

第三章执行摘要

  • 全球纤维肌痛治疗市场概况
  • 绘製纤维肌痛治疗的全球生态系图
  • 纤维肌痛治疗的全球绝对商机
  • 全球纤维肌痛治疗市场各地区吸引力
  • 纤维肌痛治疗的区域市场分析
  • 全球纤维肌痛治疗市场（按分销管道）
  • 全球纤维肌痛治疗市场（依药物类别）
  • 未来市场机会
  • 全球市场区隔

第四章 市场展望

  • 纤维肌痛治疗的全球市场前景
  • 市场演变
  • 市场驱动因素
    • 新型纤维肌痛疗法核准上市
    • 强大的产品平臺和纤维肌痛的兴起
  • 限制因素
    • 纤维肌痛治疗的副作用
    • 仿单标示外学名药的采用率增加
  • 可能性
    • 加强研发力度，开发治疗纤维肌痛症的新治疗方法
  • COVID-19 对全球纤维肌痛治疗市场的影响
  • 宏观经济分析
  • 波特五力分析
    • 新进入者的威胁
    • 替代品的威胁
    • 供应商的议价能力
    • 买家的议价能力
    • 竞争对手之间的竞争
  • 定价分析

第五章 药品市场分类

  • 概述
  • 抗忧郁症
  • 抗惊厥药
  • 麻醉剂
  • 肌肉鬆弛剂

第六章 治疗市场

  • 概述
  • 治疗
  • 治疗
  • 生活方式的改变

第七章 终端用户市场

  • 概述
  • 医院
  • 诊所

第八章 区域市场

  • 概述
  • 北美洲
    • 北美市场概述
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲市场概述
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 亚太市场概述
    • 中国
    • 印度
    • 日本
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲市场概述
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 中东和非洲市场概述
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

第九章 竞争态势

  • 概述
  • 公司市场排名分析
  • 区域足迹
  • 公司在各行业的足迹
  • 王牌矩阵
    • 积极的
    • 前线
    • 新兴
    • 创新者

第十章 公司简介

  • PFIZER
  • INNOVATIVE MED CONCEPTS
  • NOVARTIS AG
  • ELI LILLY & COMPANY
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • INTEC PHARMA LTD.
  • ABBVIE
  • FSD PHARMA
  • MERCK & CO.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
Product Code: 36116

Fibromyalgia Treatment Market Size And Forecast

Fibromyalgia Treatment Market size was valued at USD 1811.76 Million in 2024 and is projected to reach USD 2508.28 Million by 2032, growing at a CAGR of 4.15% from 2026 to 2032.

  • Fibromyalgia treatment refers to the range of medical therapies, medications, and other solutions designed to manage the symptoms of fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties.
  • This is primarily utilized by healthcare providers, including hospitals, clinics, and pharmacies, to treat patients suffering from fibromyalgia.
  • Medications like pain relievers, antidepressants, and anti-seizure drugs, as well as physical therapy and counseling, are commonly used in fibromyalgia management.
  • It is used to improve the quality of life for fibromyalgia patients by alleviating symptoms, reducing pain, and managing associated conditions such as sleep disturbances and depression.
  • As the understanding of fibromyalgia improves, the market is expanding with new treatment options, catering to the growing number of patients seeking relief from this chronic, often debilitating condition.
  • Fibromyalgia is a long-term disorder that causes pain throughout the body, fatigue, and difficulties with sleep, memory, and mood.
  • Due to the chronic nature of the condition and the variety of symptoms associated with it, treatment is primarily focused on managing the symptoms rather than curing the disease.

Global Fibromyalgia Treatment Market Dynamics

The key market dynamics that are shaping the global fibromyalgia treatment market include:

Key Market Drivers

  • Increasing Prevalence of Fibromyalgia: The rising number of people diagnosed with fibromyalgia globally is driving demand for effective treatment options.
  • Growing Awareness of the Disorder: Enhanced public awareness and better diagnostic methods are leading to more individuals seeking treatment.
  • Advancements in Drug Development: The National Institutes of Health (NIH) reported funding for fibromyalgia research increased from $13 million in 2019 to $18 million in 2023, a 38% increase. According to the FDA, there are currently over 25 clinical trials specifically focused on fibromyalgia treatments in various phases. Pharmaceutical companies are focusing on the development of new and more effective drugs for fibromyalgia, driving market growth.
  • Improved Healthcare Infrastructure: Expanding healthcare facilities, especially in developing regions, is increasing access to fibromyalgia treatments.
  • Rising Demand for Non-Pharmaceutical Therapies: The growing preference for alternative therapies like cognitive behavioral therapy (CBT) and physical rehabilitation is boosting market growth.

Key Market Challenges:

  • Difficulty in Diagnosis: Fibromyalgia can be difficult to diagnose due to overlapping symptoms with other conditions, hindering timely treatment.
  • Limited Awareness in Developing Regions: Lack of awareness and diagnostic tools in certain regions limits the market potential.
  • Side Effects of Existing Medications: Many fibromyalgia drugs have significant side effects, affecting patient adherence and market growth.
  • High Treatment Costs: The expense of medications and therapies can limit access, particularly in low-income areas.
  • Lack of Curative Treatment: The absence of a permanent cure restricts the market to symptom management, limiting long-term effectiveness.

Key Market Trends:

  • Development of Personalized Medicine: The increasing focus on personalized treatment approaches is gaining traction in the fibromyalgia market.
  • Integration of Telemedicine: Telemedicine platforms are becoming more prevalent, allowing patients easier access to consultations and follow-ups.
  • Non-Pharmaceutical Treatment Growth: More patients are opting for alternative therapies such as mindfulness, acupuncture, and exercise programs.
  • Combination Therapies: There is a growing trend toward combining pharmaceutical and non-pharmaceutical treatments for more comprehensive care.
  • Research in Biologics: New research is being conducted into biologics and novel therapies that target the root causes of fibromyalgia symptoms, promising more effective solutions in the future.

Global Fibromyalgia Treatment Market Regional Analysis

Here is a more detailed regional analysis of the fibromyalgia treatment market:

North America

  • The North American region significantly dominates the Global Fibromyalgia Treatment Market owing to the rising prevalence of fibromyalgia and a well-established healthcare infrastructure.
  • According to the Centers for Disease Control and Prevention (CDC), fibromyalgia affects about 4 million US adults, approximately 2% of the adult population.
  • The National Fibromyalgia Association reports that the condition is more prevalent in women, with females accounting for 75-90% of cases.
  • The U.S. leads the market, driven by increased diagnosis rates, greater public awareness of the condition, and the availability of advanced treatment options.
  • The presence of key pharmaceutical companies focused on developing innovative therapies for fibromyalgia further strengthens the region's market position.
  • Growing research and development activities aimed at discovering new drugs and treatment modalities have fueled market expansion.
  • Government initiatives and healthcare programs in the U.S. and Canada to promote awareness and provide access to treatment for chronic pain conditions have played a crucial role in market growth.
  • The rising demand for personalized medicine and alternative therapies such as cognitive behavioral therapy (CBT), physiotherapy, and mindfulness practices is also influencing the market dynamics in North America.
  • The high cost of treatment and the side effects associated with some medications remain key challenges in the region.
  • Despite this, North America's dominant healthcare infrastructure and ongoing advancements in fibromyalgia treatment continue to drive market growth.

Asia Pacific

  • The Asia Pacific region is anticipated to witness the fastest growth in the Global Fibromyalgia Treatment Market, driven by increasing awareness of chronic pain conditions and improving healthcare infrastructure.
  • Countries such as China, Japan, India, and South Korea are contributing to market expansion as healthcare access becomes more widespread and diagnosis rates for fibromyalgia improve.
  • The region's growing aging population is also a key factor, as fibromyalgia tends to affect older adults more frequently.
  • Rising healthcare expenditure and the availability of affordable treatment options are facilitating the market's growth in Asia Pacific.
  • Governments in countries like India and China are initiating healthcare reforms aimed at increasing the accessibility of pain management therapies, which is positively impacting the fibromyalgia treatment market.
  • Despite these advancements, challenges such as low awareness in rural areas and limited availability of specialized treatment centers pose obstacles to market growth.
  • The increasing focus on research and development, along with the growing demand for non-invasive treatments and alternative therapies like acupuncture and herbal medicines, is expected to drive continued growth in the Asia Pacific fibromyalgia treatment market in the coming years.

Global Fibromyalgia Treatment Market: Segmentation Analysis

The Global Fibromyalgia Treatment Market is segmented based on Drug Class, Treatment, End-Users, and Geography.

Fibromyalgia Treatment Market, By Drug Class

  • Antidepressants
  • Anticonvulsants
  • Analgesics
  • Muscle Relaxants

Based on drug class, the Global Fibromyalgia Treatment Market is segmented into Antidepressants, Anticonvulsants, Analgesics, and Muscle Relaxants. The Antidepressant segment significantly dominates the Global Fibromyalgia Treatment Market owing to their effectiveness in reducing pain and improving mood in fibromyalgia patients.

Fibromyalgia Treatment Market, By Treatment

  • Medication
  • Therapy
  • Lifestyle Changes

Based on treatment, the Global Fibromyalgia Treatment Market is segmented into Medication, Therapy, and Lifestyle Changes. The Medication segment significantly dominates the Global Fibromyalgia Treatment Market owing to its central role in symptom management, with drugs like antidepressants and pain relievers commonly prescribed.

Fibromyalgia Treatment Market, By End-Users

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies

Based on end-users, the Global Fibromyalgia Treatment Market is segmented into Hospitals, Clinics, Retail Pharmacies, and Online Pharmacies. Hospitals significantly dominate the Global Fibromyalgia Treatment Market owing to the availability of specialized care and advanced treatment options for fibromyalgia patients.

Fibromyalgia Treatment Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the global fibromyalgia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region significantly dominates the Global Fibromyalgia Treatment Market owing to the rising prevalence of fibromyalgia and a well-established healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC), fibromyalgia affects about 4 million US adults, approximately 2% of the adult population. The National Fibromyalgia Association reports that the condition is more prevalent in women, with females accounting for 75-90% of cases. The U.S. leads the market, driven by increased diagnosis rates, greater public awareness of the condition, and the availability of advanced treatment options.

Key Players

The "Global Fibromyalgia Treatment Market" study report provides valuable insight with an emphasis on the global market. The major players in the market are Fizer, Innovative Med Concepts, Novartis AG, Eli Lilly & Company, Sun Pharmaceutical Industries Ltd., Intec Pharma Ltd., AbbVie, FSD Pharma, Merck & Co., Teva Pharmaceutical Industries Ltd., Lupin Limited, Viatris Inc., Tonix Pharmaceuticals Holding Corp., and Aptinyx Inc.

  • This section offers in-depth analysis through a company overview, position analysis, the regional and industrial footprint of the company, and the ACE matrix for insightful competitive analysis. The section also provides an exhaustive analysis of the financial performances of mentioned players in the given market.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Fibromyalgia Treatment Market Key Developments

  • In August 2022, Aptinyx Inc. announced the results from a Phase 2b clinical study that evaluated the effects of NYX-2925 in patients with fibromyalgia. The study revealed that NYX-2925 did not achieve statistically significant separation from placebo on the primary endpoint, which measured the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12.
  • In October 2020, Eli Lily announced a collaboration with Daiichi Sankyo in Japan for the commercialization of Galcanezumab, an anti-CGRP antibody potentially used to treat migraines. Under this agreement, Daiichi Sankyo was responsible for the sales and distribution of Galcanezumab, while Eli Lily Japan retained the marketing license, pending marketing approval.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP-DOWN APPROACH
  • 2.10 RESEARCH FLOW
  • 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

  • 3.1 GLOBAL FIBROMYALGIA TREATMENT MARKET OVERVIEW
  • 3.2 GLOBAL FIBROMYALGIA TREATMENT ECOLOGY MAPPING
  • 3.3 GLOBAL FIBROMYALGIA TREATMENT ABSOLUTE MARKET OPPORTUNITY
  • 3.4 GLOBAL FIBROMYALGIA TREATMENT MARKET ATTRACTIVENESS, BY REGION
  • 3.5 GLOBAL FIBROMYALGIA TREATMENT MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.6 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (USD MILLION)
  • 3.7 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS (USD MILLION)
  • 3.8 FUTURE MARKET OPPORTUNITIES
  • 3.9 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

  • 4.1 GLOBAL FIBROMYALGIA TREATMENT MARKET OUTLOOK
  • 4.2 MARKET EVOLUTION
  • 4.3 MARKET DRIVERS
    • 4.3.1 APPROVAL AND LAUNCH OF NOVEL FIBROMYALGIA TREATMENT DRUGS
    • 4.3.2 STRONG PRODUCT PIPELINE AND INCREASING OCCURRENCE OF FIBROMYALGIA
  • 4.4 RESTRAINTS
    • 4.4.1 SIDE EFFECTS OF THE DRUGS USED FOR THE TREATMENT OF FIBROMYALGIA
    • 4.4.2 HIGHER ADOPTION OF OFF-LABEL AND GENERIC DRUGS
  • 4.5 OPPORTUNITIES
    • 4.5.1 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR THE DEVELOPMENT OF NEW THERAPIES FOR THE TREATMENT OF FIBROMYALGIA
  • 4.6 IMPACT OF COVID19 ON GLOBAL FIBROMYALGIA TREATMENT MARKET
  • 4.7 MACROECONOMIC ANALYSIS
  • 4.8 PORTER'S FIVE FORCES ANALYSIS
    • 4.8.1 THREAT OF NEW ENTRANTS
    • 4.8.2 THREAT OF SUBSTITUTES
    • 4.8.3 BARGAINING POWER OF SUPPLIERS
    • 4.8.4 BARGAINING POWER OF BUYERS
    • 4.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 4.9 PRICING ANALYSIS

5 MARKET, BY DRUG CLASS

  • 5.1 OVERVIEW
  • 5.2 ANTIDEPRESSANTS
  • 5.3 ANTICONVULSANTS
  • 5.4 ANALGESICS
  • 5.5 MUSCLE RELAXANTS

6 MARKET, BY TREATMENT

  • 6.1 OVERVIEW
  • 6.2 MEDICATION
  • 6.3 THERAPY
  • 6.4 LIFESTYLE CHANGES

7 MARKET, BY END-USERS

  • 7.1 OVERVIEW
  • 7.2 HOSPITALS
  • 7.2 CLINICS

8 MARKET, BY GEOGRAPHY

  • 8.1 OVERVIEW
  • 8.2 NORTH AMERICA
    • 8.2.1 NORTH AMERICA MARKET SNAPSHOT
    • 8.2.2 U.S.
    • 8.2.3 CANADA
    • 8.2.4 MEXICO
  • 8.3 EUROPE
    • 8.3.1 EUROPE MARKET SNAPSHOT
    • 8.3.2 GERMANY
    • 8.3.3 U.K.
    • 8.3.4 FRANCE
    • 8.3.5 ITALY
    • 8.3.6 SPAIN
    • 8.3.7 REST OF EUROPE
  • 8.4 ASIA PACIFIC
    • 8.4.1 ASIA PACIFIC MARKET SNAPSHOT
    • 8.4.2 CHINA
    • 8.4.3 INDIA
    • 8.4.4 JAPAN
    • 8.4.5 REST OF ASIA PACIFIC
  • 8.5 LATIN AMERICA
    • 8.5.1 LATIN AMERICA MARKET SNAPSHOT
    • 8.5.2 BRAZIL
    • 8.5.3 ARGENTINA
    • 8.5.4 REST OF LATIN AMERICA
  • 8.6 MIDDLE EAST AND AFRICA
    • 8.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
    • 8.6.2 UAE
    • 8.6.3 SAUDI ARABIA
    • 8.6.4 SOUTH AFRICA
    • 8.6.5 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 COMPANY MARKET RANKING ANALYSIS,
  • 9.3 COMPANY REGIONAL FOOTPRINT
  • 9.4 COMPANY INDUSTRY FOOTPRINT
  • 9.5 ACE MATRIX
    • 9.5.1 ACTIVE
    • 9.5.2 CUTTING EDGE
    • 9.5.3 EMERGING
    • 9.5.4 INNOVATORS

10 COMPANY PROFILES

  • 10.1 PFIZER
    • 10.1.1 COMPANY OVERVIEW
    • 10.1.2 COMPANY INSIGHTS
    • 10.1.3 SEGMENT BREAKDOWN
    • 10.1.4 PRODUCT BENCHMARKING
    • 10.1.5 KEY DEVELOPMENTS
    • 10.1.6 WINNING IMPERATIVES
    • 10.1.7 CURRENT FOCUS & STRATEGIES
    • 10.1.8 THREAT FROM COMPETITION
    • 10.1.9 SWOT ANALYSIS
  • 10.2 INNOVATIVE MED CONCEPTS
    • 10.2.1 COMPANY OVERVIEW
    • 10.2.2 COMPANY INSIGHTS
    • 10.2.3 SEGMENT BREAKDOWN
    • 10.2.4 PRODUCT BENCHMARKING
    • 10.2.5 KEY DEVELOPMENTS
    • 10.2.6 WINNING IMPERATIVES
    • 10.2.7 CURRENT FOCUS & STRATEGIES
    • 10.2.8 THREAT FROM COMPETITION
    • 10.2.9 SWOT ANALYSIS
  • 10.3 NOVARTIS AG
    • 10.3.1 COMPANY OVERVIEW
    • 10.3.2 COMPANY INSIGHTS
    • 10.3.3 SEGMENT BREAKDOWN
    • 10.3.4 PRODUCT BENCHMARKING
    • 10.3.5 KEY DEVELOPMENTS
    • 10.3.6 WINNING IMPERATIVES
    • 10.3.7 CURRENT FOCUS & STRATEGIES
    • 10.3.8 THREAT FROM COMPETITION
    • 10.3.9 SWOT ANALYSIS
  • 10.4 ELI LILLY & COMPANY
    • 10.4.1 COMPANY OVERVIEW
    • 10.4.2 COMPANY INSIGHTS
    • 10.4.3 SEGMENT BREAKDOWN
    • 10.4.4 PRODUCT BENCHMARKING
    • 10.4.5 KEY DEVELOPMENTS
    • 10.4.6 WINNING IMPERATIVES
    • 10.4.7 CURRENT FOCUS & STRATEGIES
    • 10.4.8 THREAT FROM COMPETITION
    • 10.4.9 SWOT ANALYSIS
  • 10.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 10.5.1 COMPANY OVERVIEW
    • 10.5.2 COMPANY INSIGHTS
    • 10.5.3 SEGMENT BREAKDOWN
    • 10.5.4 PRODUCT BENCHMARKING
    • 10.5.5 KEY DEVELOPMENTS
    • 10.5.6 WINNING IMPERATIVES
    • 10.5.7 CURRENT FOCUS & STRATEGIES
    • 10.5.8 THREAT FROM COMPETITION
    • 10.5.9 SWOT ANALYSIS
  • 10.6 INTEC PHARMA LTD.
    • 10.6.1 COMPANY OVERVIEW
    • 10.6.2 COMPANY INSIGHTS
    • 10.6.3 SEGMENT BREAKDOWN
    • 10.6.4 PRODUCT BENCHMARKING
    • 10.6.5 KEY DEVELOPMENTS
    • 10.6.6 WINNING IMPERATIVES
    • 10.6.7 CURRENT FOCUS & STRATEGIES
    • 10.6.8 THREAT FROM COMPETITION
    • 10.6.9 SWOT ANALYSIS
  • 10.7 ABBVIE
    • 10.7.1 COMPANY OVERVIEW
    • 10.7.2 COMPANY INSIGHTS
    • 10.7.3 SEGMENT BREAKDOWN
    • 10.7.4 PRODUCT BENCHMARKING
    • 10.7.5 KEY DEVELOPMENTS
    • 10.7.6 WINNING IMPERATIVES
    • 10.7.7 CURRENT FOCUS & STRATEGIES
    • 10.7.8 THREAT FROM COMPETITION
    • 10.7.9 SWOT ANALYSIS
  • 10.8 FSD PHARMA
    • 10.8.1 COMPANY OVERVIEW
    • 10.8.2 COMPANY INSIGHTS
    • 10.8.3 SEGMENT BREAKDOWN
    • 10.8.4 PRODUCT BENCHMARKING
    • 10.8.5 KEY DEVELOPMENTS
    • 10.8.6 WINNING IMPERATIVES
    • 10.8.7 CURRENT FOCUS & STRATEGIES
    • 10.8.8 THREAT FROM COMPETITION
    • 10.8.9 SWOT ANALYSIS
  • 10.9 MERCK & CO.
    • 10.9.1 COMPANY OVERVIEW
    • 10.9.2 COMPANY INSIGHTS
    • 10.9.3 SEGMENT BREAKDOWN
    • 10.9.4 PRODUCT BENCHMARKING
    • 10.9.5 KEY DEVELOPMENTS
    • 10.9.6 WINNING IMPERATIVES
    • 10.9.7 CURRENT FOCUS & STRATEGIES
    • 10.9.8 THREAT FROM COMPETITION
    • 10.9.9 SWOT ANALYSIS
  • 10.10 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 10.10.1 COMPANY OVERVIEW
    • 10.10.2 COMPANY INSIGHTS
    • 10.10.3 SEGMENT BREAKDOWN
    • 10.10.4 PRODUCT BENCHMARKING
    • 10.10.5 KEY DEVELOPMENTS
    • 10.10.6 WINNING IMPERATIVES
    • 10.10.7 CURRENT FOCUS & STRATEGIES
    • 10.10.8 THREAT FROM COMPETITION
    • 10.10.9 SWOT ANALYSIS

LIST OF TABLES

  • TABLE1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
  • TABLE 2 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 3 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 4 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY GEOGRAPHY, 2022-2030 (USD MILLION)
  • TABLE 5 NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 6 NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 7 NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 8 U.S. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 9 U.S. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE10 CANADA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE11 CANADA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE12 MEXICO FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE13 MEXICO FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE14 EUROPE FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE15 EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE16 EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE17 GERMANY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE18 GERMANY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE19 U.K. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 20 U.K. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 21 FRANCE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 22 FRANCE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 23 ITALY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 24 ITALY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 25 SPAIN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 26 SPAIN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 27 REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 28 REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 29 ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 30 ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 31 ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 32 CHINA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 33 CHINA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 34 INDIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 35 INDIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 36 JAPAN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 37 JAPAN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS 2022-2030 (USD MILLION)
  • TABLE 38 REST OF ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 39 REST OF ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 40 LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 41 LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 42 LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 43 BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 44 BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 45 ARGENTINA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 46 ARGENTINA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 47 REST OF LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 48 REST OF LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 49 MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 50 MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 51 MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 52 UAE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 53 UAE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 54 SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 55 SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 56 SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 57 SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 58 REST OF MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 59 REST OF MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 60 COMPANY MARKET RANKING ANALYSIS
  • TABLE 61 COMPANY REGIONAL FOOTPRINT
  • TABLE 62 COMPANY INDUSTRY FOOTPRINT
  • TABLE 63 PFIZER INC.: PRODUCT BENCHMARKING
  • TABLE 64 PFIZER INC.: WINNING IMPERATIVES
  • TABLE 65 NOVARTIS AG: PRODUCT BENCHMARKING
  • TABLE 66 NOVARTIS AG: WINNING IMPERATIVES
  • TABLE 67 ABBVIE: PRODUCT BENCHMARKING
  • TABLE 68 ABBVIE: KEY DEVELOPMENTS
  • TABLE 69 ABBVIE: WINNING IMPERATIVES
  • TABLE 70 ELI LILLY AND COMPANY: PRODUCT BENCHMARKING
  • TABLE 71 VIRIOS THERAPEUTICS, INC.: PRODUCT BENCHMARKING
  • TABLE 72 VIRIOS THERAPEUTICS, INC.: KEY DEVELOPMENTS
  • TABLE 73 ASTELLAS PHARMA: PRODUCT BENCHMARKING
  • TABLE 74 ASTELLAS PHARMA: KEY DEVELOPMENTS
  • TABLE 75 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT BENCHMARKING
  • TABLE 76 INTEC PHARMA S.R.O.: PRODUCT BENCHMARKING
  • TABLE 77 APTINYX INC.: PRODUCT BENCHMARKING
  • TABLE 78 APTINYX INC.: KEY DEVELOPMENTS

LIST OF FIGURES

  • FIGURE1 GLOBAL FIBROMYALGIA TREATMENT MARKET SEGMENTATION
  • FIGURE 2 RESEARCH TIMELINES
  • FIGURE 3 DATA TRIANGULATION
  • FIGURE 4 MARKET RESEARCH FLOW
  • FIGURE 5 DATA SOURCES
  • FIGURE 6 GLOBAL FIBROMYALGIA TREATMENT MARKET GEOGRAPHICAL ANALYSIS, 2023-30
  • FIGURE 7 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (USD MILLION)
  • FIGURE 8 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS (USD MILLION)
  • FIGURE 9 FUTURE MARKET OPPORTUNITIES
  • FIGURE10 NORTH AMERICA DOMINATED THE MARKET IN 2021
  • FIGURE11 GLOBAL FIBROMYALGIA TREATMENT MARKET OUTLOOK
  • FIGURE12 PORTER'S FIVE FORCES ANALYSIS FOR GLOBAL FIBROMYALGIA TREATMENT MARKET
  • FIGURE13 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
  • FIGURE14 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS
  • FIGURE15 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY GEOGRAPHY, 2022-2030 (USD MILLION)
  • FIGURE16 U.S. MARKET SNAPSHOT
  • FIGURE17 CANADA MARKET SNAPSHOT
  • FIGURE18 MEXICO MARKET SNAPSHOT
  • FIGURE19 GERMANY MARKET SNAPSHOT
  • FIGURE 20 U.K. MARKET SNAPSHOT
  • FIGURE 21 FRANCE MARKET SNAPSHOT
  • FIGURE 22 ITALY MARKET SNAPSHOT
  • FIGURE 23 SPAIN MARKET SNAPSHOT
  • FIGURE 24 REST OF EUROPE MARKET SNAPSHOT
  • FIGURE 25 CHINA MARKET SNAPSHOT
  • FIGURE 26 INDIA MARKET SNAPSHOT
  • FIGURE 27 JAPAN MARKET SNAPSHOT
  • FIGURE 28 REST OF ASIA PACIFIC MARKET SNAPSHOT
  • FIGURE 29 BRAZIL MARKET SNAPSHOT
  • FIGURE 30 ARGENTINA MARKET SNAPSHOT
  • FIGURE 31 REST OF LATIN AMERICA MARKET SNAPSHOT
  • FIGURE 32 UAE MARKET SNAPSHOT
  • FIGURE 33 SAUDI ARABIA MARKET SNAPSHOT
  • FIGURE 34 SOUTH AFRICA MARKET SNAPSHOT
  • FIGURE 35 REST OF MIDDLE EAST AND AFRICA MARKET SNAPSHOT
  • FIGURE 36 KEY STRATEGIC DEVELOPMENTS
  • FIGURE 37 ACE MATRIX
  • FIGURE 38 PFIZER INC.: COMPANY INSIGHT
  • FIGURE1 PFIZER INC.: SEGMENT BREAKDOWN
  • FIGURE 2 PFIZER INC.: SWOT ANALYSIS
  • FIGURE 3 NOVARTIS AG: COMPANY INSIGHT
  • FIGURE 4 NOVARTIS AG: BREAKDOWN
  • FIGURE 5 NOVARTIS AG: SWOT ANALYSIS
  • FIGURE 6 ABBVIE: COMPANY INSIGHT
  • FIGURE 7 ABBVIE: SEGMENT BREAKDOWN
  • FIGURE 8 ABBVIE: SWOT ANALYSIS
  • FIGURE 9 ELI LILLY AND COMPANY: COMPANY INSIGHT
  • FIGURE10 ELI LILLY AND COMPANY: BREAKDOWN
  • FIGURE11 VIRIOS THERAPEUTICS, INC.: COMPANY INSIGHT
  • FIGURE12 ASTELLAS PHARMA: COMPANY INSIGHT
  • FIGURE13 ASTELLAS PHARMA: SEGMENT BREAKDOWN
  • FIGURE14 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY INSIGHT
  • FIGURE15 SUN PHARMACEUTICAL INDUSTRIES LTD.: SEGMENT BREAKDOWN
  • FIGURE16 INTEC PHARMA S.R.O.: COMPANY INSIGHT
  • FIGURE17 APTINYX INC.: COMPANY INSIGHT
  • FIGURE18 PRISMIC PHARMACEUTICALS: COMPANY INSIGHT
  • FIGURE19 PRISMIC PHARMACEUTICALS: PRODUCT BENCHMARKING